WORLDWIDE BIOSPECIMEN ACCESS

TRANS-HIT BIO CORPORATE PRESENTATION SUMMARY

Leading Biospecimen Procurement CRO

Headquartered in Montreal, Canada with: An EU branch located in Paris, France A presence in Eastern Europe (Ukraine and Russia) and

Asia (India, China) through strategic partnerships

Prospective and Retrospective projects 60+ partnered biobanks collecting from 300+

hospitals all over the world 1000+ requests managed since inception Site management team (THB and partners) of

30+ nurses and CRAs Project Management team of 8 PhDs with an

academic background and a proven expertise in biomarker development

1,600+ biobanks detailed in THB proprietary database

Our Vision

Biospecimens needed for discovery and validation purposes,historically remnant samples from clinical labs, have become muchmore sophisticated and therefore harder to collect

Exponential growth of the biomarker industry has led to an increaseddemand from End Users who often compete with peers for the samesamples: Access to biospecimens is often the main bottleneck in R&D

A pragmatic solution is to partner with i) academic/hospital teamsthat have a higher recruitment rate ii) biobanks and clinical sites inforeign locations that may be less accessible than those in westerncountries

Successfully partnering with these teams requires scientificknowledge and a presence in the field that makes our business totallydifferent from brokerage firms that mainly sell products off the shelf

At the same time, industry’s expectations towards the faster andsimplified procurement process offered by the latter are legitimate

Global Reach

Proprietary Network: 300 Hospitals 30,000 Hospital beds 1 million admissions per year 10 million out-patients per year 500,000 patients under chemotherapy

Direct interaction with independent academicsites and biobanks in North America and inWestern Europe

Operations through strategic partners in othercountries:

Disclosure and Traceability

THB REMOVES THE BLINDFOLD! THB discloses Biospecimen Sources to End Users

(and vice versa) via MTAs and favors directinteractions between them

We believe a transparent chain-of-custody: to be the best route to goodwill from tier one

academic sites for whom acknowledgment oftheir contribution is at least as important as thefinancial compensation

better complies with basic QA guidelines (seeGLP, GCP, or GMP guidelines) and the onlyapproach to ensure procurement of uniquepatient samples

High Value added Biospecimens

THB has built an outstanding reputation forunrivaled collection capability in the high added-value segment, i.e.: FFPE blocks with or without matched biofluids

and fresh tissue High Quality associated data Mutation/Expression status

Year 2016

200+ requests met through 120 prospectivecollections and 80 retrospective searches

32,000 biospecimens sourced Top 5 segments: Oncology, Infectious diseases,

CNS, Healthy tissues, and Metabolic disorders

Proven and Effective Procurement Process

Feasibility study done through our proprietarynetwork of partnered biobanks

Availability in retrospective collections usuallyconfirmed within 1 to 3 working days

If necessary, accessibility to samples among1,600 biobanks registered in our proprietarydatabase and feasibility of a prospectivecollection among partnered clinical sites areevaluated

MSAs and Umbrella MTAs already in place withpartners